Inside Health Policy, March 4, 2024: NCHR was interviewed regarding the FDA rescinding accelerated approval for Pepaxto for multiple myeloma. We explain that the FDA’s new “’streamlined’ path to reverse approval decisions still takes years even after there is proof that patients taking the drug are more likely to die.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
A Closer Look at Aduhelm, CTE, and the Super Bowl: Insights from STAT Readers
February 11, 2024: NCHR was quoted in Medriva regarding our commentary on the evidence FDA should require to prove safety and efficacy of treatments used by older patients, which was also discussed in Letters to the Editor and comments to STAT.
Read More »Deep flaws in FDA oversight of medical devices — and patient harm — exposed in lawsuits and records
CBS News, December 20, 2023: CBS News article dives into the lack of FDA oversight within the medical device industry. Increased patient harm is exposed in lawsuits and records.
Read More »FDA Warned of Overstepping Authority With Lab Test Rule Proposal
Bloomberg Law, December 7: Bloomberg Law news article describes the strong opposition to FDA’s plan to regulate lab-developed tests (LDTs). We explain why patients can’t trust the results of these diagnostic tests unless FDA makes sure they are accurate.
Read More »FDA’s Janet Woodcock to retire early next year
STAT News, November 16, 2023: Principal Deputy FDA Commissioner Janet Woodcock will retire from the FDA in early 2024 after almost 40 years at the agency, many as a powerful and controversial leader. We explain how her legacy has tarnished the FDA’s reputation.
Read More »